Navigation Links
Rubicon Genomics Expands Distribution in Europe and Asia
Date:12/12/2013

ANN ARBOR, Mich., Dec. 12, 2013 /PRNewswire/ -- Rubicon Genomics, Inc., (Rubicon), a leader in the development and commercialization of innovative nucleic acid library preparation products used in research and clinical testing, today announced that it has partnered with additional distributors globally to expand availability of its products, including ThruPLEX®-FD Prep Kits and PicoPLEX™-WGA Kits.

Three new distribution partnerships have been signed for Europe.  They include Amplitech for France, HPST for the Czech Republic and LuBio Science for Switzerland.  Rubicon also completed new distribution agreements in Asia and the Middle East.  They include Recenttec for Japan, Prisma Biotech for Taiwan and S.M. Chemical for Thailand.  Custom Science will provide distribution services to Australia and New Zealand.  A well-established local biomedical distributor is supporting sales of Rubicon's products in Qatar.

James Koziarz, PhD, CEO of Rubicon Genomics, commented, "These agreements reflect our strategy of enhancing our existing global distribution channel by partnering with companies that know their local markets and are able to provide a high level of technical service and support.  They extend our reach in growing sequencing markets around the globe and enable our customers to access our products without the additional cost and complications of shipping from the US to global destinations."

ThruPLEX®-FD Prep Kits for Illumina® NGS platforms streamline library preparation for fragmented DNA/cDNA and reduce sample input amounts to picogram levels.  ThruPlex-FD's patented technology delivers a highly efficient and user-friendly process that takes place in a single tube in less than 2 hours.  ThruPLEX-FD provides consistent and reliable results for applications including DNA-seq, RNA-seq and ChiP-seq and is especially useful for clinical samples such as plasma and FFPE.

PicoPLEX™-WGA Kits amplify DNA to yield a highly reproducible library from a single cell.  The product is widely used in the IVF market to identify aneuploidy and copy number variation.  PicoPLEX WGA's patented technology is optimized for amplification of single copy genomic DNA with input concentrations as low as 15 picograms.  The easy-to-use single tube protocol reduces handling errors and background and dramatically improves time to results.

More information on Rubicon's distributors can be found at: http://rubicongenomics.com/how-to-buy/distributors/.

About Rubicon Genomics
Rubicon Genomics, Inc. is a leader in the development and commercialization of innovative sample-specific nucleic acid library preparation products used in research and clinical testing on NGS, microarray, and q-PCR platforms.  The company's core competency is the creation of more efficient molecular biology tools for genetic, epigenetic and expression analysis of difficult clinical samples to facilitate gene-based research, drug development and diagnostics.  Privately-held Rubicon is located in Ann Arbor, Michigan. For more information, visit www.rubicongenomics.com.Contacts:

MediaRubicon GenomicsBarbara LindheimJamie Wibbenmeyer, PhDBLL Partners, LLCBusiness Development(212) 584-227jwibbenmeyer@rubicongenomics.com  

blindheim@bllbiopartners.com  


'/>"/>
SOURCE Rubicon Genomics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
2. Catching up with the Genomic Era in Oncology: Key Considerations for Incorporating Genomics into Oncology Drug Development, a New and Upcoming Webinar Hosted by Xtalks
3. Tute Genomics appoints Dr. Mingfu Zhu as Director of Bioinformatics
4. BioNano Genomics Announces the Adoption of Irys System by the Garvan Institute of Medical Research
5. Biogas Consortium Using Genedata Selector for Metagenomics-based Process Optimization
6. Healthcare VC Dr. Dinesh Patel to serve on Tute Genomics Board of Directors
7. Tute Genomics Launches at 2013 ASHG Conference
8. BioNano Genomics Announces The Purchase Of The Irys System By The Chinese Academy Of Sciences And Tel Aviv University
9. NextCODE Health Launches Operations with Exclusive License to Leverage deCODE genetics Genomics Platform for Sequence-Based Clinical Diagnostics, and $15 Million in Venture Financing
10. Claritas Genomics to Sequence Exomes for VA Million Veteran Program with Ion Torrent Next-Generation Sequencers
11. Chinese Leader in Genomics Joins Science Center's Port Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... Village, CA (PRWEB) , ... August 17, 2017 ... ... technology for cancer research and personalized medicine, today announced the launch of a ... Kansas City, Missouri. The study’s goal is to evaluate the potential for early ...
(Date:8/16/2017)... ... 2017 , ... Today, 3Bar Biologics Inc ., the ... funding from an impressive group of investors, including Rev1 Ventures, Maumee Ventures, Ohio ... investment, 3Bar is broadening availability of its groundbreaking offering that uses naturally occurring ...
(Date:8/15/2017)... NC (PRWEB) , ... August 15, 2017 , ... ... 2017, celebrating 10 years of successes helping medical technology companies and inventors develop and ... to a renowned full-service national engineering firm with a portfolio of clients in the ...
(Date:8/15/2017)... , ... August 15, 2017 , ... The Conference ... on Immuno-Oncology 360° (IO360°) programming through a series of upcoming panels and events. The ... 7-9, 2018, at The Roosevelt Hotel in New York City. , “With our experience ...
Breaking Biology Technology:
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
Breaking Biology News(10 mins):